Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Foscarbidopa/foslevadopa - Abbvie

Next Previous
Drug Profile

Foscarbidopa/foslevadopa - Abbvie

Alternative Names: ABBV 951; foscarbidopa/foslevodopa; Foslevodopa/foscarbidopa; Levodopa/carbidopa prodrug; PRODUODOPA; VYALEV; Vyalev

Latest Information Update: 11 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AbbVie
  • Class Antiparkinsonians; Aromatic amino acids; Carboxylic acids; Catecholamines; Hydrazines; Phosphates; Small molecules
  • Mechanism of Action Decarboxylase inhibitors; Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Parkinson's disease

Most Recent Events

  • 27 Apr 2026 AbbVie completes the phase III extension trial for Parkinson's disease in USA and Australia (SC) (NCT04750226)
  • 17 Apr 2026 Abbvie completes a phase III trial in Parkinson's disease in Australia, Belgium, Canada, Denmark, Italy, Japan, Netherlands, Spain, United Kingdom, USA , Germany, Russia, Sweden(SC) (NCT04379050)
  • 05 Apr 2025 Updated efficacy and adverse events data from a phase III trial in Parkinson's disease presented at 77th Annual Meeting of the American Academy of Neurology 2025 (AAN-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top